Results 141 to 150 of about 729,992 (290)

Oncovascular Resection in Pelvic Exenteration: A Systematic Review

ANZ Journal of Surgery, EarlyView.
Risk of bias assessment using ROBINS‐1 V2. Selection of the reported result (D7) was judged based on omission of key expected outcomes, including margin status (R0 resection), postoperative complications and mortality. Studies not reporting these outcomes were classified as serious risk of bias, while those with broadly complete but non‐pre‐specified ...
Joshua Richard Burke, Yasmin Oskui, Imogen Samuel, Jonathan Wild, Kilian G. Brown, Jonathan Ghosh, Paul A. Sutton   +6 more
wiley   +1 more source

Carcinoma dell’endometrio: nuovi fattori eziopatogenetici [PDF]

, 2009
Ferrara, Cinzia
core   +1 more source

Evaluation of CD10 Expression in Endometrial Carcinoma: A Systematic Review. [PDF]

Iran J Pathol
Ashtari S, Pasha AE, Awad TB, Rezaei M, Mehrabi MM.   +4 more
europepmc   +1 more source

Cancer pain: current practice and emerging targets

British Journal of Pharmacology, EarlyView.
Cancer pain (CP) arises from a complex interplay between the tumour and its microenvironment. Many patients experience a mixed pain phenotype that encompasses nociceptive, neuropathic and neuroinflammatory mechanisms, and vary across tumour type and disease stage. Despite decades of intensive research, the mainstay of cancer pain treatment is still non‐
Yi Ye, Marcin Chwistek, Zhiting Gong, Vanessa Uzonwanne, Xiaojie Shi, Arpad Szallasi   +5 more
wiley   +1 more source

Targeting KRAS for cancer therapy

British Journal of Pharmacology, EarlyView.
In recent years, therapeutics targeted against KRAS proto‐oncogene GTPase (KRAS)‐mutant cancers have seen significant progress. Herein we outline the biology and epidemiology of KRAS alterations at the lineage and allele levels, reviewing the clinical evidence for KRASG12C inhibition from the discovery of the recessive switch pocket to sotorasib ...
Jianlong Jia, Ruonan Liu, Tonia A. Adamide, Isis E. Fernandez, Georgios T. Stathopoulos   +4 more
wiley   +1 more source

Arrhythmias associated with immune checkpoint inhibitor therapy—A clinical perspective

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitors (ICIs) have transformed cancer therapy but are associated with a growing spectrum of cardiovascular immune‐related adverse events. Among these, arrhythmias represent a rare yet potentially life‐threatening complication. ICI‐induced arrhythmias encompass a wide clinical spectrum, including atrial arrhythmias, conduction ...
Dong Wang, Melanie Ricke‐Hoch, David Duncker, Johann Bauersachs, Dominik Berliner   +4 more
wiley   +1 more source

Mixed endometrial carcinoma: is it time to profile the two components separately? [PDF]

Front Oncol
Musettini G, Pretelli P, Giusti A, Cupini S, Coltelli L, De Luca F, De Maio E, Finale C, Masini LC, Soria G, Cirigliano G, Viacava P, Donati S, Valsuani C, Caparello C, Lucchesi M, Furfaro I, Antonelli A, Abate S, Bracco GL, Marrai R, Liut M, Masoni S, Pini C, Mignogna M, Cocuzza P, Ginori A, Vivaldi F, Acconci G, Arrighi G, Barletta MT, Barbara C, Stasi I, Farnesi A, Marini A, Pellino A, Sammarco E, Rosada J, Orlandi F, Cavazzana A, Allegrini G.   +40 more
europepmc   +1 more source

ENDOMETRIAL CARCINOMA : LAPAROSCOPIC MANAGEMENT

, 1998
Since 1988 endometrial cancer is considered to be a surgically staged disease by FIGO and therefore in the treatment of endometrial carcinoma surgery is the "back-bone" (Creasman, Onnis).
R. Tozzi, G. Crovini, B. Andrei, LITTA, PIETRO SALVATORE, C. Vasile   +4 more
core  

NTAQ1 Promotes Hepatocellular Carcinoma Growth by Facilitating the Protein Degradation of the Tumor Suppressor PRDM2

Cancer Science, EarlyView.
Copy number variation analysis in The Cancer Genome Atlas identified NTAQ1 as a potential driver of HCC progression. NTAQ1 accelerates tumor growth by promoting the degradation of the tumor suppressor protein PRDM2, thereby impairing DNA repair and suppressing apoptosis. These findings indicate that NTAQ1 could be a valuable target for the treatment of
Tomohiko Ikehara, Hajime Otsu, Taro Tobo, Kiyotaka Hosoda, Tadashi Abe, Masahiro Hashimoto, Yusuke Nakano, Katsushi Dairaku, Yuya Ono, Yuki Miyata, Chihiro Matsumoto, Takanari Tatsumi, Satoshi Higuchi, Takashi Ofuchi, Akinori Tsujimoto, Yuki Ando, Qingjiang Hu, Yusuke Yonemura, Akira Shimizu, Takaaki Masuda, Yuji Soejima, Koshi Mimori   +21 more
wiley   +1 more source

Tissue Factor‐High Ovarian Clear Cell Carcinoma Shows Immune‐Cold Features and Preclinical Activity of Tisotumab Vedotin

Cancer Science, EarlyView.
F3/TF‐high ovarian clear cell carcinoma exhibits an immune‐cold phenotype characterized by reduced immune‐cell fractions and attenuated cancer‐cell interferon programs, with frequent B7‐H4 co‐expression. Patient‐derived models show preclinical sensitivity to the TF‐directed antibody–drug conjugate tisotumab vedotin.
Yutaro Mori, Ryo Tamura, Kotaro Takahashi, Kaoru Yamawaki, Tatsuya Ishiguro, Teiichi Motoyama, Koji Okamoto, Kosuke Yoshihara   +7 more
wiley   +1 more source